DOAC Reversal

By: Team TTB Prepared: Feb. 18, 2025

Overview

Managing bleeding in patients on Direct Oral Anticoagulants (DOACs) requires a rapid and informed approach. This module provides guidance on identifying DOAC-related bleeds, selecting appropriate reversal strategies, and balancing the risks of thromboembolism. It covers both specific and non-specific reversal agents, laboratory testing considerations, and practical steps for emergency and non-emergency situations, ensuring you can make evidence-based decisions when treating DOAC-associated bleeding.

Treat The Bleed is a scientific initiative made possible through an unrestricted educational grant from Octapharma Canada Inc, a global leader in the research and development of treatments for rare, inherited bleeding disorders.

treatthebleed©2025

Got an idea?

Have an idea for an educational topic or feature that could improve learning on Treat The Bleed? We invite you to contribute by submitting learning modules, articles, or other resources that align with our mission. Reach out to us to start the conversation.

Get in touch with us